Alnylam PHARMACEUTICALS, Inc. (ALNY) intrinsic value & 10-year financials
Alnylam PHARMACEUTICALS, Inc. (ALNY) has a Graham intrinsic value of $77.39 per share. At $231.83 on Oct 17, 2026, the stock trades 200% above that value. Over the last 10 fiscal years revenue grew 62.4% a year to $3.7B, with an average return on invested capital of 373.6%.
- Graham intrinsic value
- $77.39
- Share price (Oct 17, 2026)
- $231.83
- Price vs Graham value
- 200% above
- Market cap
- $31.2B
- Revenue (FY2025)
- $3.7B
- Revenue growth (10-yr CAGR)
- 62.4%
- ROIC (10-yr avg)
- 373.6%
- Free cash flow (FY2025)
- $465.4M
ALNY 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $3.7B | $313.7M | $2.33 | $465.4M | 13.5% | -74.2% |
| FY2024 | $2.2B | -$278.2M | -$2.18 | -$42.6M | -7.9% | 17.9% |
| FY2023 | $1.8B | -$440.2M | -$3.52 | $41.9M | -15.4% | 36.3% |
| FY2022 | $1.0B | -$1.1B | -$9.30 | -$613.3M | -75.7% | 4131.3% |
| FY2021 | $844.3M | -$852.8M | -$7.20 | -$718.1M | -83.9% | -82.0% |
| FY2020 | $492.9M | -$858.3M | -$7.46 | -$685.3M | -168.1% | -76.3% |
| FY2019 | $219.8M | -$886.1M | -$8.11 | -$418.6M | -427.5% | -80.5% |
| FY2018 | $74.9M | -$761.5M | — | -$689.5M | -1087.6% | -53.1% |
| FY2017 | $89.9M | -$490.9M | — | -$487.0M | -556.2% | -37.2% |
| FY2016 | $47.2M | -$410.1M | — | -$372.3M | -900.3% | -46.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ALNYLAM PHARMACEUTICALS, INC. is a consistent compounder, expanding top-line revenue at 62.4% annually over the past decade.
ALNYLAM PHARMACEUTICALS, INC. has historically struggled to out-earn its cost of capital, averaging just -31.1% ROIC.
ALNYLAM PHARMACEUTICALS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ALNYLAM PHARMACEUTICALS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $77.39 per share.